Showing results (101-110 of 117) with videos related to
Sort By:
Pageof 12
The Journal of Infectious Diseases|January 8, 2019
Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest PeriodPaul Spearman, Georgia D Tomaras, David C Montefiori, et al.The Journal of Infectious Diseases|September 2, 2005
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjectsPaul A Goepfert, Helen Horton, M Juliana McElrath, et al.Vaccine|October 20, 2006
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul A Goepfert, Georgia D Tomaras, Helen Horton, et al.Journal of Virology|July 29, 2016
Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus MacaquesSmita S Iyer, Sailaja Gangadhara, Blandine Victor, et al.Science Advances|July 4, 2025
Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)-vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trialPaul Spearman, Hong Jin, Peng Xiao, et al.Plos One|November 3, 2018
DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trialKatherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, et al.Proceedings of the National Academy of Sciences of the United States of America|August 27, 2014
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humansAli H Ellebedy, Florian Krammer, Gui-Mei Li, et al.Vaccine|November 11, 2008
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trialPaul Spearman, Spyros Kalams, Marnie Elizaga, et al.JAMA|October 8, 2014
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trialRobert B Belshe, Sharon E Frey, Irene L Graham, et al.Ebiomedicine|February 2, 2024
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trialMaurine D Miner, Allan deCamp, Nicole Grunenberg, et al.Pageof 12